Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Corradini P, et al. Among authors: lucesole m. Blood. 2002 Jan 1;99(1):75-82. doi: 10.1182/blood.v99.1.75. Blood. 2002. PMID: 11756155 Free article.
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Dodero A, Lucesole M, Patriarca F, Rambaldi A, Scimè R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A. Corradini P, et al. Among authors: lucesole m. J Clin Oncol. 2005 Sep 20;23(27):6690-8. doi: 10.1200/JCO.2005.07.070. J Clin Oncol. 2005. PMID: 16170177 Clinical Trial.
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P. Olivieri A, et al. Among authors: lucesole m. Biol Blood Marrow Transplant. 2005 Aug;11(8):627-36. doi: 10.1016/j.bbmt.2005.05.002. Biol Blood Marrow Transplant. 2005. PMID: 16041313 Free article.
Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis.
Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, Lucesole M, Poloni A, Offidani M, Candela M, Centurioni R, Leoni P. Olivieri A, et al. Among authors: lucesole m. Eur J Haematol. 2004 Jan;72(1):10-7. doi: 10.1046/j.0902-4441.2004.00171.x. Eur J Haematol. 2004. PMID: 14962257 Clinical Trial.
Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80 degrees C.
Montanari M, Capelli D, Poloni A, Massidda D, Brunori M, Spitaleri L, Offidani M, Lucesole M, Masia MC, Balducci F, Refe C, Piani M, Leoni P, Olivieri A. Montanari M, et al. Among authors: lucesole m. Transfusion. 2003 Jan;43(1):42-9. doi: 10.1046/j.1537-2995.2003.00271.x. Transfusion. 2003. PMID: 12519429
Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
Goteri G, Olivieri A, Ranaldi R, Lucesole M, Filosa A, Capretti R, Pieramici T, Leoni P, Rubini C, Fabris G, Lo Muzio L. Goteri G, et al. Among authors: lucesole m. Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):421-31. doi: 10.1177/039463200601900218. Int J Immunopathol Pharmacol. 2006. PMID: 16831308 Free article.
Conditioning regimens in acute myeloid leukemia.
Visani G, Malagola M, Guiducci B, Lucesole M, Loscocco F, Gabucci E, Paolini S, Piccaluga PP, Isidori A. Visani G, et al. Among authors: lucesole m. Expert Rev Hematol. 2014 Aug;7(4):465-79. doi: 10.1586/17474086.2014.939066. Expert Rev Hematol. 2014. PMID: 25025371 Review.
Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.
Olivieri A, Scortechini I, Capelli D, Montanari M, Lucesole M, Gini G, Troiani M, Offidani M, Poloni A, Masia MC, Raggetti GM, Leoni P. Olivieri A, et al. Among authors: lucesole m. Bone Marrow Transplant. 2004 Oct;34(8):693-702. doi: 10.1038/sj.bmt.1704643. Bone Marrow Transplant. 2004. PMID: 15300235
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M, Lucesole M, Brunori M, Massidda D, Offidani M, Leoni P, Olivieri A. Capelli D, et al. Among authors: lucesole m. Br J Haematol. 2000 Aug;110(2):300-7. doi: 10.1046/j.1365-2141.2000.02149.x. Br J Haematol. 2000. PMID: 10971385 Free article. Clinical Trial.
14 results